Mackenzie Financial Corp bought a new stake in GRIFOLS S A/S (NASDAQ:GRFS) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 802,342 shares of the biotechnology company’s stock, valued at approximately $16,929,000. Mackenzie Financial Corp owned about 0.12% of GRIFOLS S A/S at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the company. Royal Bank of Canada raised its holdings in shares of GRIFOLS S A/S by 6.2% in the second quarter. Royal Bank of Canada now owns 190,316 shares of the biotechnology company’s stock valued at $4,016,000 after purchasing an additional 11,128 shares during the last quarter. UBS Group AG raised its holdings in shares of GRIFOLS S A/S by 27.0% in the second quarter. UBS Group AG now owns 1,322,161 shares of the biotechnology company’s stock valued at $27,898,000 after purchasing an additional 280,695 shares during the last quarter. Nuveen Asset Management LLC purchased a new stake in shares of GRIFOLS S A/S in the second quarter valued at about $1,854,000. OneAscent Financial Services LLC purchased a new stake in shares of GRIFOLS S A/S in the second quarter valued at about $312,000. Finally, Citadel Advisors LLC raised its holdings in shares of GRIFOLS S A/S by 41.8% in the second quarter. Citadel Advisors LLC now owns 710,460 shares of the biotechnology company’s stock valued at $14,991,000 after purchasing an additional 209,278 shares during the last quarter. Institutional investors own 17.91% of the company’s stock.
NASDAQ GRFS traded up $0.12 during trading hours on Friday, reaching $19.90. 29,300 shares of the company were exchanged, compared to its average volume of 1,536,038. GRIFOLS S A/S has a 1 year low of $17.42 and a 1 year high of $23.03. The business’s 50 day simple moving average is $20.92 and its 200-day simple moving average is $20.17. The company has a quick ratio of 0.95, a current ratio of 2.68 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $13.60 billion, a P/E ratio of 17.03, a P/E/G ratio of 1.26 and a beta of 1.06.
Several brokerages have recently commented on GRFS. JPMorgan Chase & Co. upgraded shares of GRIFOLS S A/S from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $21.00 to $22.50 in a report on Thursday, June 27th. BidaskClub downgraded shares of GRIFOLS S A/S from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 18th. Zacks Investment Research upgraded shares of GRIFOLS S A/S from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, ValuEngine upgraded shares of GRIFOLS S A/S from a “sell” rating to a “hold” rating in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $20.75.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Read More: Cost of Equity
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.